000 | 01989 a2200505 4500 | ||
---|---|---|---|
005 | 20250516030628.0 | ||
264 | 0 | _c20110715 | |
008 | 201107s 0 0 spa d | ||
022 | _a1989-7286 | ||
024 | 7 |
_a10.1016/j.oftal.2010.11.015 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aPinar-Sueiro, S | |
245 | 0 | 0 |
_a[Cannabinoid applications in glaucoma]. _h[electronic resource] |
260 |
_bArchivos de la Sociedad Espanola de Oftalmologia _cJan 2011 |
||
300 |
_a16-23 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aArachidonic Acids _xadministration & dosage |
650 | 0 | 4 |
_aBenzoxazines _xadministration & dosage |
650 | 0 | 4 | _aCannabinoid Receptor Agonists |
650 | 0 | 4 |
_aCannabinoid Receptor Modulators _xagonists |
650 | 0 | 4 |
_aCannabinoids _xadministration & dosage |
650 | 0 | 4 | _aDrug Administration Routes |
650 | 0 | 4 | _aDrug Evaluation, Preclinical |
650 | 0 | 4 | _aEndocannabinoids |
650 | 0 | 4 |
_aExcitatory Amino Acid Antagonists _xadministration & dosage |
650 | 0 | 4 |
_aEye Proteins _xagonists |
650 | 0 | 4 |
_aGlaucoma _xdrug therapy |
650 | 0 | 4 |
_aGlutamic Acid _xphysiology |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aIntraocular Pressure _xdrug effects |
650 | 0 | 4 | _aMammals |
650 | 0 | 4 |
_aMorpholines _xadministration & dosage |
650 | 0 | 4 |
_aNaphthalenes _xadministration & dosage |
650 | 0 | 4 |
_aNeuroprotective Agents _xadministration & dosage |
650 | 0 | 4 |
_aOptic Nerve _xdrug effects |
650 | 0 | 4 |
_aPolyunsaturated Alkamides _xadministration & dosage |
650 | 0 | 4 |
_aReceptors, Cannabinoid _xphysiology |
650 | 0 | 4 |
_aRetinal Ganglion Cells _xdrug effects |
650 | 0 | 4 |
_aVasodilator Agents _xadministration & dosage |
700 | 1 | _aRodrÃguez-Puertas, R | |
700 | 1 | _aVecino, E | |
773 | 0 |
_tArchivos de la Sociedad Espanola de Oftalmologia _gvol. 86 _gno. 1 _gp. 16-23 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.oftal.2010.11.015 _zAvailable from publisher's website |
999 |
_c20685169 _d20685169 |